Clinical Commissioning Policy: Robotic-Assisted Surgical Procedures for Prostate Cancer

Reference: NHS England B14/P/a
## NHS England INFORMATION READER BOX

### Directorate
- Medical
- Commissioning Operations
- Patients and Information
- Nursing
- Trans. & Corp. Ops.
- Commissioning Strategy
- Finance

### Publications Gateway Reference:
- 03714

### Document Purpose
- Policy

### Document Name
- B14/P/a Robotic Assisted Surgery for Prostate Cancer

### Author
- Specialised Commissioning Team, NHS England

### Publication Date
- July 2015

### Target Audience
- Local Team Assistant Directors of Specialised Commissioning;
- Regional Team IFR Leads; Finance Leads; Local Team Pharmacists;
- Chairs of Clinical Reference Groups; Members of Clinical Reference
  Groups and registered stakeholders; Acute Trust Chief Executives;
  Acute Trust Medical Directors; Acute Trust Chief Pharmacists

### Additional Circulation List
- Regional Medical Directors; Regional Directors of Specialised
  Commissioning; Regional Clinical Directors of Specialised
  Commissioning; Regional Directors of Nursing

### Description
- NHS England will routinely commission this specialised treatment in
  accordance with the criteria described in this policy.

### Cross Reference

### Superseded Docs
- (if applicable)

### Action Required

### Timing / Deadlines
- (if applicable)

### Contact Details for further information
- jeremyglyde@nhs.net for policy issues

### Document Status

This is a controlled document. Whilst this document may be printed, the electronic version posted on the intranet is the controlled copy. Any printed copies of this document are not controlled. As a controlled document, this document should not be saved onto local or network drives but should always be accessed from the intranet.

**NB:** The National Health Service Commissioning Board was established on 1 October 2012 as an executive non-departmental public body. Since 1 April 2013, the National Health Service Commissioning Board has used the name NHS England for operational purposes.
1 Executive summary

Policy Statement

NHS England will commission robotic assisted surgical techniques for the treatment of prostate cancer (i.e., radical prostatectomies for prostate cancer) in accordance with the criteria outlined in this document.

In creating this policy NHS England has reviewed this clinical condition and the options for its treatment. It has considered the place of this treatment in current clinical practice, whether scientific research has shown the treatment to be of benefit to patients, (including how any benefit is balanced against possible risks) and whether its use represents the best use of NHS resources.

This policy document outlines the arrangements for funding of this treatment for the population in England.

Equality Statement

NHS England has a duty to have regard to the need to reduce health inequalities in access to health services and health outcomes achieved as enshrined in the Health and Social Care Act 2012. NHS England is committed to fulfilling this duty as to equality of access and to avoiding unlawful discrimination on the grounds of age, gender, disability (including learning disability), gender reassignment, marriage and civil partnership, pregnancy and maternity, race, religion or belief, gender or sexual orientation. In carrying out its functions, NHS England will have due regard to the different needs of protected equality groups, in line with the Equality Act 2010. This document is compliant with the NHS Constitution and the Human Rights Act 1998. This applies to all activities for which NHS England is responsible, including policy development, review and implementation.
Plain Language Summary

Prostate cancer is the most common cancer in men, with around 35,000 men being diagnosed in England. Prostate cancer can progress slowly and as a result the range of management options is wide, ranging from ‘watchful waiting’ and active surveillance to hormone therapy and surgical/radiotherapy procedures.

This policy proposes a change to the range of surgical options available to clinical teams to treat early, or localised, prostate cancer. This is where the cancer is only in the prostate gland and has not spread into the surrounding tissues or to other parts of the body. It is also called localised prostate cancer.

Just over half of men who choose surgical treatment currently receive either open or laparoscopic surgical procedures. This policy recommends that all men with early/localised prostate cancer can also be offered robotic assisted laparoscopic surgery within a networked approach.

2 Introduction

Prostate cancer, which is a cancer of the urological system, is the most common male cancer in England. In 2011, 35,567 men were diagnosed with prostate cancer in England, with a corresponding Age Standardised Rate (ASR) of 106.7 per 100,000 population (95% Confidence Interval 105.6-107.8) (ONS, 2013).

In January 2014, the National Institute for Clinical Effectiveness (NICE) published revised clinical guidelines for the treatment and management of prostate cancer (NICE, 2014). This guideline confirmed that commissioners should consider whether to offer robotic assisted surgical techniques in the management of localised prostate cancer. It further stated that commissioners should ensure that, where the technique was to be offered that those centres should be performing at least 150 robot assisted laparoscopic radical prostatectomies per year.
Robotic Assisted Surgery (RAS) is a form of minimally invasive surgery that is increasingly used in a number of complex surgical procedures internationally. Within England, this technique has developed primarily within the field of urological cancer treatment and, alongside laparoscopic techniques, has been replacing traditional open surgical procedures. This commissioning policy relates to the treatment of prostate cancer, rather than the wider field of urological cancers which also includes: kidney, bladder, testicular and penile.

RAS carries a large capital cost and greater revenue costs as compared to either laparoscopic or open surgery. Currently providers are reimbursed for RAS procedures both through Payments by Results and via pass through payments for the cost of the robotic consumables. Therefore, both open and laparoscopic procedures cost commissioners less to perform.

This commissioning policy has been developed because:

- Over the last ten years the NHS has seen a significant increase in the use of RAS. This increase has not been subject to any national strategy either in location of provider or the clinical application where it should be supported; and
- Though NICE has recently included the use of RAS as a treatment option for the management of localised prostate cancer (specifically robot assisted radical laparoscopic prostatectomy), NHS England had not reviewed the clinical and cost effectiveness evidence relating to RAS.

3 Definitions

**Localised prostate cancer**: is where the cancer is only in the prostate and has not spread into the surrounding tissues or to other parts of the body. It is also called localised prostate cancer.

**Prostatectomy**: is the removal of the prostate gland, usually performed to treat cancer. There are two types of prostatectomy:
• Trans-urethral prostatectomy, which is used to treat BPH and sometimes to provide symptomatic relief in prostate cancer. Only part of the gland is removed in this case; and
• Radical prostatectomy, which is used to treat localised prostate cancer and involves the removal of the whole prostate gland and the attached seminal vesicles.

Radical prostatectomies can be carried out in three ways:

• Open retropubic radical prostatectomy, which is where a surgeon uses an incision in the lower abdomen to reach and remove the prostate and lymph nodes;
• Laparoscopic prostatectomy, which is where the surgeon inserts a laparoscope through small incisions in the abdominal wall to remove the prostate and nodes; and
• Robot-assisted laparoscopic radical prostatectomy, which is a variant of the laparoscopic procedure.

4 Aim and objectives

This policy aims to ensure that patients with localised prostate cancer are routinely offered RAS procedures, alongside other management options, to treat their disease.

The objectives are to:

• Support the cost-effective use of NHS resources; and
• Ensure the equitable access to RAS as an appropriate treatment option in the management of prostate cancer.

5 Epidemiology and needs assessment
5.1 Prostate cancer epidemiology

Prostate cancer is the most common cancer in men and makes up 26% of all male cancer diagnoses in England. In 2011, 35,567 men were diagnosed with prostate cancer, with a corresponding Age Standardised Rate (ASR) of 106.7 per 100,000 population (95% Confidence Interval 105.6-107.8). There were 9,123 deaths from prostate cancer in 2011 in England, translating to a mortality rate of 23.8 per 100,000 population (95% Confidence Interval 23.3-24.4) (ONS, 2014).

Prostate cancer is predominantly a disease of older men (aged 65–79 years) but around 25% of cases occur in men below the age of 65. Increased incidence and mortality is observed in men of black African or Caribbean family origin compared with white Caucasian men (NICE, 2014).

5.2 Treatment by prostatectomy

Prostatectomy is one of a range of treatments available which are dependent on the stage and severity of the disease. Other options include active surveillance, external beam radiotherapy and brachytherapy, the latter two with/without neoadjuvant hormone therapy (androgen deprivation).

Epidemiological data obtained from Public Health England (2014) shows that the rate of prostatectomies peaked in 2005 following a rise in the preceding years associated with the rapid increase in detection of cancers due to increased Prostate Specific Antigen (PSA) testing. Since 2005, the percentage of diagnosed patients who undergo a prostatectomy has remained relatively stable at approximately 13% (PHE, 2014). However, it should be noted that procedure trends remain sensitive to changes in incidence, and the impact of PSA testing rates.

The British Association of Urological Surgeons (BAUS) analysis of prostatectomy data for the UK, published in June 2013, showed that in 2013 the number of procedures performed was 3,695, by 130 surgeons in 62 Centres. This represents an increase from the 2,093 performed in 2012, where 110 surgeons performed these
across 57 Centres. This increase could be due to a number of factors, including changes in reporting processes to BAUS. These are also UK figures, and therefore a number of cases relate to practice undertaken outside of England.

The most common indication for prostatectomy is the primary treatment of prostate cancer, with 77% of procedures performed for this purpose (BAUS, 2014). Previous active surveillance (13.2%), where patients progress to surgical intervention following an increase in Prostate Specific Antigen (PSA) level, is the second most common reason for prostatectomy, with salvage therapy accounting for 0.7% of operations. For 8.7% of operations, the reason for surgery was not recorded (BAUS, 2014).

The largest proportion of prostatectomies for cancer were performed on men aged between 60-69 (57%), with 24% performed on men aged between 50-59, and 15.1% performed on men aged between 70-79 years of age.

5.2.1 Robot Assisted laparoscopic radical prostatectomy

The BAUS data shows that of the 3,695 procedures performed in 2013, 1,824 (49.7%) were performed using robotic assisted approaches.

Hospital Episode Statistics (HES) data* suggests that approximately 5,271 prostatectomies will have been undertaken to treat cancer during 2013/14 (NHS England, 2014). This data set also demonstrates that the proportion of robotic (48%) to non-robotic (52%) to be relatively even and comparable to the proportions demonstrated within the BAUS data set.

The differences in the absolute number of prostatectomies undertaken reported in BAUS and HES datasets relates to a number of factors, chiefly that: (i) BAUS reports for the United Kingdom as a whole, whereas HES data relates to England only; and (ii) BAUS reports are based on self-reported data, covering approximately 70% of surgeons.

* 2013/14 HES data search scope
# Diagnosis Code | Procedure Code
--- | ---
C61- Malignant neoplasm of prostate | M611 - Total excision of prostate and capsule of prostate
 | M612 - Retropubic prostatectomy
 | M613 - Transvesical prostatectomy
 | M614 - Perineal prostatectomy
 | M618 - Other specified open excision of prostate
 | M619 - Unspecified open excision of prostate

## 6 Evidence base

An in-depth evidence review was commissioned from Solutions for Public Health. Findings are summarised below (Solutions for Public Health, 2014). Overall, the review concluded:

- There was no compelling evidence that robot-assisted approaches impact on long term oncological outcomes when compared with laparoscopic and standard approaches.
- There is some evidence of clinical advantages from robot-assisted laparoscopic radical prostatectomy when compared with both laparoscopic and open radical procedures. These include lower risk of incontinence or sexual dysfunction, and reduced blood loss and lengths of stay, when compared to open prostatectomy.
- There was no clear evidence of particular sub-groups which might benefit from robotic approach compared to open or laparoscopic approaches. Such groups require further targeted research.
- Higher volume hospitals for robot-assisted laparoscopic radical prostatectomy are associated with better outcomes and productivity. There is no clear threshold to achieve better outcomes, but particularly small numbers of procedures appear to be especially adverse. It remains unclear how much experience is needed
before a high and stable level of skill is attained. Outcomes continue to improve even for surgeons with substantial experience.

A summary of the key findings of the evidence review are presented below.

6.1 Robot-assisted laparoscopic radical prostatectomy compared to conventional laparoscopic radical prostatectomy

The review identified two randomised controlled trials of robot-assisted laparoscopic radical prostatectomy versus conventional laparoscopic radical prostatectomy (Asimakopoulos et al. 2011, Porpiglia et al. 2013). In both of these randomised trials, no significant differences between robot-assisted and laparoscopic approaches were reported between the two surgical techniques in any perioperative or early postoperative outcome measure. Both trials reported a greater urinary continence rate at one year in men who had undergone robot-assisted surgery, but this difference was only statistically significant in one trial. In both trials, recovery of sexual function at one year was more frequent after robot-assisted surgery. In both of these studies, there were no significant differences observed in the percentage of positive surgical margins or biochemical relapse-free survival at one year.

A systematic review which included un-randomised studies reported no evidence of differences in operative time, but patients having a robot-assisted procedure had shorter length of admissions (Healthcare Improvement Scotland, 2013).

The results on positive surgical margins were contradictory. Some meta-analyses reported lower rates with robot-assisted laparoscopic radical prostatectomy; however, a meta-analysis which only included studies at lowest risk of bias reported no significant differences, in common with the two randomised trials (Healthcare Improvement Scotland, 2013).

A similar pattern was seen with urinary continence, with different results from different analyses; again, the most reliable meta-analysis showed no significant differences (Healthcare Improvement Scotland, 2013).
None of the meta-analyses showed higher rates of sexual function after robot-assisted laparoscopic radical prostatectomy compared with the laparoscopic procedure (Healthcare Improvement Scotland, 2013).

There was widespread and substantial heterogeneity in the meta-analyses reported in the Health Technology Assessment, casting doubt on the reliability of the comparisons reported.

6.2 Robot-assisted laparoscopic radical prostatectomy versus open radical prostatectomy

There were no randomised comparisons of robot-assisted laparoscopic radical prostatectomy versus open radical prostatectomy (Healthcare Improvement Scotland, 2013). Observational studies included in the Scottish review reported similar operative durations for open retropubic and robot-assisted laparoscopic radical prostatectomy, though hospital stays were shorter after the latter procedure. Rates of positive surgical margins and biochemical recurrence-free survival were similar. Blood loss was less and fewer patients needed transfusions after robot-assisted surgery (Trinh et al. 2012, Gandaglia et al. 2014). Results for overall rates of complications varied between analyses.

Rates of urinary continence and sexual function at one year were higher after robot-assisted laparoscopic radical prostatectomy (Healthcare Improvement Scotland, 2013). There were no studies reporting on health-related quality of life.

A large controlled but un-randomised study comparing open and robot-assisted laparoscopic radical prostatectomy reported similar results of the two procedures for most outcomes. Men who had robot-assisted surgery were more likely to have complications. They had shorter lengths of stay and fewer blood transfusions, but despite this, had higher costs (Gandaglia et al. 2014).
Conversely, a second similar study reported that patients undergoing robot-assisted laparoscopic radical prostatectomy were less likely to experience an intraoperative or postoperative complication. Other results were consistent with the first study, in that patients undergoing robot-assisted laparoscopic radical prostatectomy were less likely to receive a blood transfusion, and to experience a prolonged length of stay (Trinh et al. 2012).

6.3 NICE Guidance

In issuing their guidance on robotic assisted laparoscopic radical prostatectomy (NICE, 2014), NICE also acknowledged the potential for reduced transfusions and shorter length of stay compared to other surgical approaches. NICE considered the Health Technology Assessment (HTA) conducted by Close et al (2013), particularly in relation to positive surgical margin outcomes. Close et al (2013) found significantly less positive surgical margins with robot-assisted laparoscopic radical prostatectomy compared to laparoscopic prostatectomy.

Studies published since the HTA, and analysed in the evidence review (Solutions for Public Health, 2014), have found no significant difference in positive margin rates between robot-assisted laparoscopic radical prostatectomy compared to laparoscopic prostatectomy. The NICE Committee noted differences in the methodologies used within these studies, compared to the HTA, for ascertaining of positive margin rates. The NICE Committee therefore noted in the final guidance that “more weight” had been placed on the HTA result in informing their decision to approve RAS as a treatment option for prostatectomy.

6.4 Safety

Estimated blood loss is less with robot-assisted laparoscopic radical prostatectomy than with either alternative procedure. No other differences relating to safety was consistently reported in the studies analysed as part of the review.

6.5 Impact on quality of life
There is evidence that robotic approaches can improve quality of life measures through demonstrating reduced length of stay, and improved urinary continence and sexual function.

6.6 Cost effectiveness

A health economic analysis concluded that robot-assisted laparoscopic radical prostatectomy was more expensive than laparoscopic prostatectomy, but produced better outcomes, and was more cost-effective (Close et al, 2013).

The result depended on the difference in positive surgical margin rates between the two interventions and an assumption that the number of robot-assisted procedures would be at least a hundred per year. If either of these assumptions are not met – and evidence calls into question the first one – then the analysis’ results are not reliable.

7 Rationale behind the policy statement

There is reasonable evidence for the clinical effectiveness of RAS procedures in the management of localised prostate cancer, specifically relating to:

- Reducing the risk of incontinence
- Preventing sexual dysfunction
- Minimising blood-loss in theatre
- Reducing margin positive rates

The evidence review concluded that at the present time there is no evidence that using this procedure conveys any additional survival gain for those patients undergoing the procedure as compared with open or laparoscopic techniques.

To conclude, the procedure offers reasonable and discrete quality of life-gains for patients undergoing RAS as compared with open and laparoscopic techniques,
together with some efficiency savings for the healthcare system as a whole (through reduced blood-loss). Furthermore, NHS England currently commissions a significant proportion of robotic assisted laparoscopic radical prostatectomy activity, for which provider organisations have already invested substantial capital in purchasing the equipment required to deliver this.

8 Criteria for commissioning

RAS procedures will be offered as a choice alongside existing commissioned procedures (open and laparoscopic) to all patients with localised prostate cancer, where this is determined to be clinically appropriate, by specialist Multi-Disciplinary Teams (MDTs).

RAS procedures will be commissioned from networked centres performing high volumes (i.e. 150 robotic assisted laparoscopic radical prostatectomies) in line with the evidence relating to volume and outcome.

This policy has been agreed on the basis of NHS England’s understanding of the likely price of care associated with enacting the policy for all patients for whom NHS England has funding responsibility, as at the time of the policy’s adoption. Should these prices materially change, and in particular should they increase, NHS England may need to review whether the policy remains affordable and may need to make revisions to the published policy.

9 Patient Pathway

The policy does not impact on the clinical pathway. RAS is a different way of carrying out a radical prostatectomy, if used the procedure would be delivered at the same point in the clinical pathway and necessitate the same outpatient follow-up arrangements.
However, the policy may entail some provider organisations to enter into expanded clinical network arrangements to ensure that all patients can be offered all three surgical options by the Specialist Multi-disciplinary Team (SMDT).

It may be the case that, following the wider-availability of RAS procedures, some patients that currently select radiotherapy as a treatment option may instead select RAS. Currently there is no published literature available to enable this to be modelled or quantified.

10 Governance arrangements

RAS procedures shall only be undertaken in centres that:

- Undertake at least 150 robot-assisted laparoscopic radical prostatectomies per year.
- Have a recognised training programme to support the safe and effective delivery of RAS techniques.
- Undertake local audits to support continued professional learning and development.

Participate in all national audits, such as that supported by BAUS and/or RCS (NPCA).

11 Mechanism for funding

Due to indifferent classifications on the application of the Identification Rules across the country, the commissioner paying for prostate cancer surgery remains a mix of both CCGs and NHS England. Furthermore, this may well be the case for non-robotic surgery, so any shift in how the procedure is carried out may also mean a shift of commissioner paying for this treatment.
If this shift in commissioner is significant enough, this may require a baseline transfer between commissioners in order to alleviate the funding impact of one commissioner offset by the benefit of the shift to another.

Providers will continue to be reimbursed as per national NHS tariff rules applicable to the year.

12 Audit requirements

Provider organisations are expected to continue to report through BAUS Audits and/or National Prostate Cancer Audit mechanisms.

13 Documents which have informed this policy

In addition to those stated within the references section, this policy has been informed by the independent rapid evidence review (Solutions for Public Health, 2014) which assessed the evidence for using RAS to treat prostate cancer.

14 Links to other policies

This policy follows the principles set out in the ethical framework that govern the commissioning of NHS healthcare and those policies dealing with the approach to experimental treatments and processes for the management of individual funding requests (IFR).

15 Date of review

This policy is due to be reviewed in April 2017 unless information is received which indicates that the proposed review date should be brought forward or delayed.
References


National Institute for Health and Care Excellence (NICE). Prostate Cancer: Diagnosis and Treatment. Cg175. 2014. Available at: http://www.nice.org.uk/Guidance/Cg175


